These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26840916)

  • 1. Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?
    Strang J; McDonald R; Tas B; Day E
    Addiction; 2016 Apr; 111(4):574-82. PubMed ID: 26840916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radical red tape reduction by government supported nasal naloxone: the Norwegian pilot project is innovative, safe and an important contribution to further development and dissemination of take-home naloxone.
    Lobmaier PP; Clausen T
    Addiction; 2016 Apr; 111(4):586-7. PubMed ID: 26995169
    [No Abstract]   [Full Text] [Related]  

  • 3. Ethical issues and stakeholders matter.
    Dale O
    Addiction; 2016 Apr; 111(4):587-9. PubMed ID: 26995170
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal.
    Mundin G; McDonald R; Smith K; Harris S; Strang J
    Addiction; 2017 Sep; 112(9):1647-1652. PubMed ID: 28430384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comments on Strang et al. (2016): 'Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?'.
    Doe-Simkins M; Banta-Green C; Davis CS; Green TC; Walley AY
    Addiction; 2016 Oct; 111(10):1879-80. PubMed ID: 27412451
    [No Abstract]   [Full Text] [Related]  

  • 6. While we dither, people continue to die from overdose: Comments on 'Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?'.
    Coffin P; Rich J; Dailey M; Stancliff S; Beletsky L
    Addiction; 2016 Oct; 111(10):1880-1. PubMed ID: 27412566
    [No Abstract]   [Full Text] [Related]  

  • 7. Naloxone without the needle - systematic review of candidate routes for non-injectable naloxone for opioid overdose reversal.
    Strang J; McDonald R; Alqurshi A; Royall P; Taylor D; Forbes B
    Drug Alcohol Depend; 2016 Jun; 163():16-23. PubMed ID: 26996745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal naloxone soon to become part of evolving clinical practice around opioid overdose prevention.
    Dietze P; Cantwell K
    Addiction; 2016 Apr; 111(4):584-6. PubMed ID: 26995168
    [No Abstract]   [Full Text] [Related]  

  • 9. Ensure global access to naloxone for opioid overdose management.
    Balster RL; Walsh SL
    Addiction; 2016 Apr; 111(4):589-90. PubMed ID: 26995171
    [No Abstract]   [Full Text] [Related]  

  • 10. Tangled-up and blue: releasing the regulatory chokehold on take-home naloxone.
    Winstanley EL
    Addiction; 2016 Apr; 111(4):583-4. PubMed ID: 26995167
    [No Abstract]   [Full Text] [Related]  

  • 11. International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database.
    McDonald R; Danielsson Glende Ø; Dale O; Strang J
    Drug Alcohol Rev; 2018 Feb; 37(2):205-215. PubMed ID: 28597483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose.
    Krieter P; Chiang N; Gyaw S; Skolnick P; Crystal R; Keegan F; Aker J; Beck M; Harris J
    J Clin Pharmacol; 2016 Oct; 56(10):1243-53. PubMed ID: 27145977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study.
    McDonald R; Lorch U; Woodward J; Bosse B; Dooner H; Mundin G; Smith K; Strang J
    Addiction; 2018 Mar; 113(3):484-493. PubMed ID: 29143400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations.
    Avetian GK; Fiuty P; Mazzella S; Koppa D; Heye V; Hebbar P
    Curr Med Res Opin; 2018 Apr; 34(4):573-576. PubMed ID: 28535115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: a systematic review.
    Ryan SA; Dunne RB
    Pain Manag; 2018 May; 8(3):231-245. PubMed ID: 29683378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine.
    Strang J; McDonald R; Campbell G; Degenhardt L; Nielsen S; Ritter A; Dale O
    Drugs; 2019 Sep; 79(13):1395-1418. PubMed ID: 31352603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA-Approved Intranasal and Intramuscular Devices Versus a Common Improvised Nasal Naloxone Device.
    Krieter PA; Chiang CN; Gyaw S; McCann DJ
    J Clin Pharmacol; 2019 Aug; 59(8):1078-1084. PubMed ID: 30861160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Take-Home Naloxone for the Prevention of Overdose Fatalities among Heroin Users in the United Kingdom.
    Langham S; Wright A; Kenworthy J; Grieve R; Dunlop WCN
    Value Health; 2018 Apr; 21(4):407-415. PubMed ID: 29680097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Take-home emergency naloxone to prevent heroin overdose deaths after prison release: rationale and practicalities for the N-ALIVE randomized trial.
    Strang J; Bird SM; Parmar MK
    J Urban Health; 2013 Oct; 90(5):983-96. PubMed ID: 23633090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing methods of naloxone administration: A narrative review.
    Fellows SE; Coppola AJ; Gandhi MA
    J Opioid Manag; 2017; 13(4):253-260. PubMed ID: 28953317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.